Diagnosis and Clinical Management of The Leukodystrophies

Nov 6, 2020 from 8:30 a.m. - 3 p.m. (ET)


Leukodystrophy affected families and individuals continue to face barriers in diagnosis and standard of care management. This session will provide up to date information on the best diagnostic and disease management practices, with an emphasis on how to provide patient and disease centered care during the COVID-19 health emergency. Ten high-frequency and high-morbidity leukodystrophies will be covered in detail, along with rarer disease subtypes or leukodystrophy mimickers.

Agenda and Speakers: 

8:30 - 8:45 a.m. Participant log-in

8:45 a.m. Welcome Statement Speaker: Adeline Vanderver, MD

9:00 – 9:40 a.m. Molecular Diagnosis Speaker: Adeline Vanderver, MD

9:40 – 10:10 a.m. Radiologic Diagnosis Speaker: Arastoo Vossough, MD

10:10 – 10:30 a.m. AGS and other calcifying leukoencephalopathies Speaker: Adeline Vanderver, MD

10:30 – 10:50 a.m. Vanishing White Matter Disease Speaker: Van der Knaap, MD

10:50 – 11:10 a.m. tRNA synthetase Speaker: Nicole Wolf, MD

11:10 – 11:30 a.m. ALD Speaker: Florian Eichler, MD

11:30 – 11:50 a.m. AXD Speaker: Amy Waldman, MD

11:50 a.m. – 12:10 p.m. MLD Speaker: Laura Adang, MD, PhD

12:10 – 12:30 p.m. Canavan Speaker: Heather Lau, MD

12:30 – 12:50 p.m. 4H and other rare hypomyelinating conditions Speaker: Genevieve Bernard, MD

40 Minute Break

1:30 – 1:50 p.m. H-ABC Speaker: Adeline Vanderver, MD

1:50 – 2:10 p.m. PMD and PMDL Speaker: Amy Waldman, MD

2:10 – 2:30 p.m. Krabbe Speaker: Maria Escolar, MD

2:30 – 2:50 p.m. Mito leukoencephalopathy Speaker: Amy Goldstein, MD

2:50 – 3:00 p.m. Closing remarks Speaker: Zachary Corrigan

Learning Objectives:

Upon completion of this lecture, participants should be able to:

  1. Describe how to effectively and efficiently diagnose Leukodystrophy affected individuals
  2. Discuss how to use MRI features to improve diagnostic acumen
  3. Review how to manage individuals with the most common high morbidity disorders 
  4. Summarize which Leukodystrophy disorders have ongoing targeted therapies or clinical trials.

Approval of AMA PRA Category 1 Credit(s) for this lecture is pending.  If approved, physicians can claim CME credit commensurate with the extent of their participation in the activity for a $40 processing fee. Attendees who do not want to claim CME credit can register and attend this symposium at no cost.   

Contact: Shelly Norbury, (856) 397-5588, norburys@chop.edu

Register Today

Note: This session will be recorded and made available on our website. If you would like to ask a question during the event but would like to remain anonymous, please do not use your real name when signing in.